Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin (Q28195019)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: May 2006)

Language	Label	Description	Also known as
English	Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin	scientific article (publication date: May 2006)

Statements

scholarly article

0 references

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin (English)

0 references

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

atherosclerosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Per Morten Sandset

4

object named as

Per Morten Sandset

0 references

Håkan Emanuelsson

2

object named as

Håkan Emanuelsson

0 references

author name string

Steen Husted

1

0 references

Stan Heptinstall

3

0 references

Mark Wickens

5

0 references

Gary Peters

6

0 references

language of work or name

0 references

publication date

May 2006

0 references

European Heart Journal

0 references

27

0 references

9

0 references

1038-47

0 references

Clopidogrel: how good is it and how does it work?

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Antiplatelet therapy in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Platelet ADP receptor antagonists: ticlopidine and clopidogrel

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Clopidogrel resistance: a new chapter in a fast-moving story

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

The P2Y12 receptor as a therapeutic target in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Individual variations of platelet inhibition after loading doses of clopidogrel

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI754

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28195019&oldid=1800755778"